Abstract:Only ~20% of heavy drinkers develop alcohol cirrhosis (AC). While differences in metabolism, inflammation, signaling, microbiome signatures and genetic variations have been tied to the pathogenesis of AC, the key underlying mechanisms for this interindividual variability, remain to be fully elucidated. Induced pluripotent stem cell-derived hepatocytes (iHLCs) from patients with AC and healthy controls differ transcriptomically, bioenergetically and histologically. They include a greater number of lipid droplets (LDs) and LD-associated mitochondria compared to control cells. These pre-pathologic indicators are effectively reversed by Aramchol, an inhibitor of stearoyl-CoA desaturase. Bioenergetically, AC iHLCs have lower spare capacity, slower ATP production and their mitochondrial fuel flexibility towards fatty acids and glutamate is weakened. MARC1 and PNPLA3, genes implicated by GWAS in alcohol cirrhosis, show to correlate with lipid droplet-associated and mitochondria-mediated oxidative damage in AC iHLCs. Knockdown of PNPLA3 expression exacerbates mitochondrial deficits and leads to lipid droplets alterations. These findings suggest that differences in mitochondrial bioenergetics and lipid droplet formation are intrinsic to AC hepatocytes and can play a role in its pathogenesis.

What problem does this paper attempt to address?

The problem that this paper attempts to solve is to understand the pathological mechanism of alcohol - associated cirrhosis (AC), especially to explore the differences in susceptibility to alcoholic cirrhosis among individuals. Although about 20% of heavy drinkers will develop alcoholic cirrhosis, the specific pathogenic mechanisms and individual differences have not been fully elucidated. By using hepatocytes (iHLCs) derived from patient - derived induced pluripotent stem cells, the author aims to reveal the bioenergetics characteristics of AC and its role in the occurrence of the disease. ### Research Background - **Alcohol - associated cirrhosis (AC)**: Only about 20% of heavy drinkers will develop AC, indicating the existence of individual differences. - **Metabolism, inflammation, signal transduction, microbiome characteristics and genetic variation**: These factors are related to the occurrence of AC, but the specific mechanisms are still unclear. - **Induced pluripotent stem cell - derived hepatocytes (iHLCs)**: iHLCs obtained from AC patients and healthy controls have significant differences in transcriptome, bioenergetics and histology, including more lipid droplets (LDs) and mitochondria - related lipid droplets. ### Research Methods - **Generate iHLCs**: Generate iHLCs from the peripheral blood cells of AC patients and healthy controls, and conduct detailed bioenergetics analysis. - **Comparative analysis**: Compare the differences between AC iHLCs and healthy iHLCs by means of RNA sequencing, biochemical detection and microscopic imaging. - **Drug intervention experiment**: Treat iHLCs with Aramchol (an SCD inhibitor) and observe its effects on lipid droplet accumulation and mitochondrial function. ### Main Findings 1. **Lipid droplet accumulation and mitochondrial function**: - There are more and larger lipid droplets in AC iHLCs, and the association between lipid droplets and mitochondria is closer. - AC iHLCs show lower spare respiratory capacity, slower ATP production and weakened mitochondrial fuel flexibility. 2. **Differences in gene expression**: - RNA sequencing results show that there are 343 differentially expressed genes in AC iHLCs, involving the down - regulation of multiple pathways such as the electron transport chain and oxidative phosphorylation. - The up - regulated pathways include the PI3K - Akt signaling pathway, lipogenesis, MAPK signaling pathway, etc. 3. **Roles of PNPLA3 and MARC1**: - PNPLA3 and MARC1 are co - localized with mitochondria and lipid droplets in AC iHLCs, and knocking down PNPLA3 expression will lead to the formation of larger lipid droplets. - These findings suggest that PNPLA3 and MARC1 may play important roles in the pathological process of AC. 4. **Role of Aramchol**: - Aramchol can reduce lipid droplet accumulation in AC iHLCs, improve mitochondrial function, and reduce the level of the cell senescence marker β - galactosidase. ### Conclusion This study reveals the inherent differences in bioenergetics and lipid droplet formation in AC iHLCs, emphasizing the key roles of mitochondrial dysfunction and lipid droplet accumulation in the pathogenesis of AC. In addition, the study also shows that Aramchol may be a potential drug for the treatment of AC. ### Formula Display - **Difference in the number of lipid droplets**: \[ \text{AC iHLCs} = 4.1\times\text{H iHLCs} \] - **Mitochondrial spare respiratory capacity**: \[ \text{AC iHLCs} = 62\%\text{ of H iHLCs} \] - **ATP production**: \[ \text{AC iHLCs} = 48\%\text{ of H iHLCs} \] These findings provide a new perspective for understanding the pathological mechanism of AC and a theoretical basis for future treatment strategies.

A patient-based iPSC-derived hepatocyte model of alcohol-associated cirrhosis reveals bioenergetic insights into disease pathogenesis

Development of alcoholic liver disease model for drug evaluation from human induced pluripotent stem cell derived liver organoids

Dysregulation of innate cell types in the hepatic immune microenvironment of alcoholic liver cirrhosis

Unique and Shared Molecular Mechanisms of Alcoholic and Non-Alcoholic Liver Cirrhosis Identified Through Transcriptomics Data Integration

Donor-Dependent and Other Nondefined Factors Have Greater Influence on the Hepatic Phenotype Than the Starting Cell Type in Induced Pluripotent Stem Cell Derived Hepatocyte-Like Cells

Single-cell Profiling of Intrahepatic Immune Cells Reveals an Expansion of Tissue-resident Cytotoxic CD4+ T Lymphocyte Subset Associated With Pathogenesis of Alcoholic-associated Liver Diseases

Primary Alcohol-Activated Human and Mouse Hepatic Stellate Cells Share Similarities in Gene-Expression Profiles

Integrated Transcriptomic and Proteomic Analysis Identifies Plasma Biomarkers of Hepatocellular Failure in Alcohol-Associated Hepatitis

Visium spatial transcriptomics and proteomics identifies novel hepatic cell populations and transcriptomic signatures of alcohol‐associated hepatitis

Fat-Specific Protein 27/CIDEC Promotes Development of Alcoholic Steatohepatitis in Mice and Humans

Hepatic stellate cells and innate immunity in alcoholic liver disease

Dissecting compounded hepatocyte injury in a model of MASLD progression from human induced pluripotent stem cells

Loss of hepatic DRP1 exacerbates alcoholic hepatitis by inducing megamitochondria and mitochondrial maladaptation

Modeling alcohol-associated liver disease in humans using adipose stromal or stem cell-derived organoids

Alcohol-Associated Liver Disease Outcomes: Critical Mechanisms of Liver Injury Progression

Kupffer cell diversity maintains liver function in alcohol-associated liver disease

The Integrated "Multiomics" Landscape at Peak Injury and Resolution From Alcohol-Associated Liver Disease

Ablation of secreted phosphoprotein‐1 in hepatocytes increases fatty acid oxidation and ameliorates alcohol‐associated liver disease

Identification of Shared and Unique Key Biomarkers of Alcohol Liver Cirrhosis and Non-Alcoholic Steatohepatitis Through Machine Learning Network-Based Algorithms

Identification of integrated proteomics and transcriptomics signature of alcohol-associated liver disease using machine learning

Key regulators of hepatic stellate cell activation in alcohol liver Disease: A comprehensive review